Cytisinicline demonstrated quit rates at least as effective as varenicline yet with significantly fewer side effects in a 679-subject Phase 3 study led by Dr. Natalie Walker, Associate Professor at the University of Auckland.
Chantix® is a registered trademark of Pfizer Inc.
ORCA-1 Program Infographic. Click image to enlarge.
Achieve Life Sciences Announces Statistically Significant Improvement in Quit Rates for Simplified Cytisinicline Dosing Schedule in Phase 2b ORCA-1 Dose-Selection Trial. 3.0 mg, 3 times daily selected as dose for future clinical development.